Riastap: first concentrated fibrinogen product

Human fibrinogen (Riastap) is now available from CSL Behring for the treatment of bleeding in congenital hypofibrinogenaemia or afibrinogenaemia with bleeding tendency.

As a concentrated product, Riastap requires a low infusion volume
As a concentrated product, Riastap requires a low infusion volume


Fibrinogen plays an essential role in haemostasis. In the presence of thrombin, activated coagulation factor XIII and calcium ions, fibrinogen is converted into a fibrin clot. Riastap is a concentrated fibrinogen replacement product prepared from human plasma.1


In a pivotal phase II pharmacokinetic study, 14 patients with afibrinogenaemia received a single 70mg/kg iv infusion of human fibrinogen concentrate. After one hour, maximum clot firmness had increased by a mean of 8.9mm from baseline (p<0.0001). Four mild adverse reactions were reported, none of which were serious or related to study drug.2


  1. Riastap Summary of Product Characteristics, March 2011.
  2. Manco-Johnson MJ et al. J Thromb Haemost 2009; 7: 2064–9.

View Riastap drug record

Further information: CSL

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more